Nancy Hong Ph.D Overview

  • Primary Position
  • President

  • Primary Industry
  • Healthcare

  • Med. Deal Size

  • Med. Valuation

Nancy Hong Ph.D General Information

Biography

Dr. Nancy Hong serves as President at Archmont Biopharma. Dr. Hong served as Managing Director at RiverVest Venture Partners. She served as Board Member at Bluejay Therapeutics. She also served as Board member at Akrevia Therapeutics and SeQure DX. She served as Board Member of Xilio Therapeutics. She served as Board Member at Scout Bio. She serves as Principal at BioMed Ventures. She joined BioMed Ventures in April 2013. Previously she was a senior analyst at Forward Ventures and advised biotech and pharma companies, including the Genomics Institute of the Novartis Research Foundation, entering new areas of research. From 2002 to 2006 Dr. Hong was a senior scientist at Phenomix where she directed a scientific group, managed pharma collaborations, and evaluated research opportunities. Dr. Hong trained in the areas of immunology and oncology, and she was a postdoctoral fellow of The Leukemia & Lymphoma Society with Nobel-laureate Dr. J. Michael Bishop at the University of California, San Francisco. Dr. Hong received a Bachelor of Science with honors in biology from the California Institute of Technology and a Ph.D. in Molecular and Cellular Biology from the University of California at Berkeley. She served as Board Member at Biolinq.

Contact Information

Primary Position
Education
University of California, Berkeley, Ph.D. (Doctor of Philosophy)
California Institute of Technology, BS (Bachelor of Science)
Gender
Female
Address
  • 101 South Hanley Road
  • Suite 1850
  • Saint Louis, MO 63105
  • United States

Nancy Hong Ph.D Positions (1)

Firm name Firm type Title Location Industry Since
Archmont Biopharma Company President Saint Louis, MO Drug Discovery

Nancy Hong Ph.D Lead Partner on Deals (9)

Nancy Hong Ph.D has been the lead partner on 9 deals. Their latest deal was with Biolinq, a monitoring equipment company. The deal was made for on 17-Oct-2022.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Biolinq 17-Oct-2022 Later Stage VC (Series B) Completed Monitoring Equipment San Diego, CA
Bluejay Therapeutics 16-Aug-2022 Completed Drug Discovery San Mateo, CA
Scout Bio 19-Oct-2021 Completed Biotechnology Philadelphia, PA
Bluejay Therapeutics 17-Jun-2021 Completed Drug Discovery San Mateo, CA
SeQure DX 02-Apr-2021 Completed Biotechnology Waltham, MA
Xilio Therapeutics 23-Feb-2021 Completed Drug Discovery Waltham, MA
Xilio Therapeutics 02-Mar-2020 Completed Drug Discovery Waltham, MA
Scout Bio 29-Mar-2019 Early Stage VC (Series B) Completed Biotechnology Philadelphia, PA
Scout Bio 27-Feb-2018 Early Stage VC (Series A) Completed Biotechnology Philadelphia, PA

Nancy Hong Ph.D Network (116)

Board Members (60)

Name Company Representing Location From
Tiffany Yu Xilio Therapeutics F-Prime Capital Waltham, MA
Daniel Curran Xilio Therapeutics Takeda Ventures Waltham, MA
Xilio Therapeutics MRL Ventures Fund Waltham, MA
SeQure DX SeQure DX Waltham, MA
Bluejay Therapeutics Self San Mateo, CA

Portfolio Executives (50)

Name Company Role Deal date Location
David Arida Biolinq Chief Operating Officer 17-Oct-2022 San Diego, CA
Andrew Woodmansee Biolinq Vice President, Legal Affairs 17-Oct-2022 San Diego, CA
Biolinq Chief Executive Officer & Board Member 17-Oct-2022 San Diego, CA
Biolinq Co-Founder, President & Co-Chief Operating Officer 17-Oct-2022 San Diego, CA
Biolinq Co-Founder, Chief Technology Officer & President 17-Oct-2022 San Diego, CA

Fund Team Members (6)

Name Investor Fund Fund Location
Niall O'Donnell Ph.D RiverVest Venture Partners RiverVest Venture Fund V Saint Louis, MO
Niall O'Donnell Ph.D RiverVest Venture Partners Archer Seed Fund Saint Louis, MO
RiverVest Venture Partners Saint Louis, MO
RiverVest Venture Partners Saint Louis, MO
RiverVest Venture Partners Saint Louis, MO

Nancy Hong Ph.D Affiliated Funds (4)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Archer Seed Fund RiverVest Venture Partners Venture Capital - Early Stage Closed 2016
RiverVest Venture Fund V RiverVest Venture Partners Venture Capital - Early Stage Closed 2020
RiverVest Venture Fund III RiverVest Venture Partners Venture Capital - Early Stage Fully Invested 2014
RiverVest Venture Fund IV RiverVest Venture Partners Venture Capital - Early Stage Closed 2018

Nancy Hong Ph.D FAQs

  • Who is Nancy Hong Ph.D?

    Dr. Nancy Hong serves as President at Archmont Biopharma.

  • How much does Nancy Hong Ph.D typically invest?

    Nancy Hong Ph.D's median deal size is .

  • What is Nancy Hong Ph.D’s main position?

    Nancy Hong Ph.D’s primary position is President.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »